NCT03612856View on ClinicalTrials.gov

Safety and Efficacy Study of AB023 (Xisomab 3G3) in End Stage Renal Disease Patients on Chronic Hemodialysis

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

October 29, 2018

Primary Completion Date

July 6, 2019

Study Completion Date

July 6, 2019

Conditions
End Stage Renal DiseaseThrombosis
Interventions
DRUG

AB023- Dose 1

Participants will receive a single dose of 0.25 mg/kg AB023.

DRUG

AB023-Dose 2

Participants will receive a single dose of 0.5 mg/kg AB023.

DRUG

placebo

Participants will receive a single dose of placebo.

Trial Locations (1)

32809

Orlando Clinical Research Center, Orlando

Sponsors

Lead Sponsor

Aronora, Inc.
All Listed Sponsors
lead

Aronora, Inc.

INDUSTRY

NCT03612856 - Safety and Efficacy Study of AB023 (Xisomab 3G3) in End Stage Renal Disease Patients on Chronic Hemodialysis | Biotech Hunter | Biotech Hunter